Bayer/Kumetrix
This article was originally published in The Gray Sheet
Executive Summary
Bayer will evaluate Kumetrix' silicon micro-needle technology for application in diabetic blood glucose monitoring over the next two to four months under an exclusive agreement. A hand-held meter using a micro-needle "the size of a human hair" is currently in pilot clinical studies at Kumetrix and uses a blood sample 1/100th the size of a drop of blood to make sampling "painless," Kumetrix claims. Additional agreements between Bayer and Union City, California-based Kumetrix would be needed for development and licensing of the technology for commercial use, assuming a positive initial evaluation by Bayer